CTOs on the Move

New Jersey Precision Technology

www.njpt.com

 
New Jersey Precision Technology is a Mountainside, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.njpt.com
  • 1081 Bristol Rd
    Mountainside, NJ USA 07092
  • Phone: 908.232.8847

Executives

Name Title Contact Details

Similar Companies

Audentes Therapeutics

Audentes is a biotechnology company committed to the development and commercialization of innovative new medicines for people with serious, rare muscle diseases. We are a passionate, energetic team driven by the goals of improving the lives of patients and building a successful business. We take pride in strong, global relationships with the patient, research, and medical communities.

XtalPi

XtalPi is a pharmaceutical technology company that is reinventing the industry’s approach to drug research and development with its Intelligent Digital Drug Discovery and Development (ID4) platform.

Logical Therapeutics

Logical Therapeutics is a Foxboro, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cellino Biotech

Personalized regenerative medicines at scale.

Gritstone Bio

Gritstone bio brings together a group of distinguished scientific founders and advisors, a highly experienced and diverse leadership team and a seasoned and successful board of directors to tackle fundamental challenges at the intersection of cancer genomics, immunotherapy and other precision therapy areas, specifically in COVID-19 and HIV. With our unique approach to immuno-oncology and infectious diseases, we seek to generate a therapeutic immune response by leveraging insights into the immune system`s ability to recognize and destroy diseased cells by targeting select antigens. We started with a focus on tumor-specific neoantigens and more recently extended our programs to include viral antigens displayed on the surface of virus-infected cells. The biology underlying immune system recognition of targets on the surface of abnormal cells is common to both anti-tumor and anti-viral immunity. Consequently, we believe that activating and directing the immune system to these targets could offer an important opportunity to extend the benefits of immunotherapy for more patients.